Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
Treament | Trials | |||||
---|---|---|---|---|---|---|
Demonstrated or suggested benefit | Inconclusive results | Uncertain results | Safety results | |||
Immunosuppressants drugs | inconclusive results for: deaths (time to event analysis only); clinical deterioration; clinical improvement (21-day); clinical improvement (28-day); clinical improvement (7-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; mechanical ventilation; viral clearance (time to event analysis only); ICU admission; recovery; related AE (TRAE); serious adverse events; superinfection; acute kidney injury ; adverse events; elevated liver enzymes; Myocardial infarction ; venous thromboembolism | suggested 7 % decrease in death or transfer to ICU but the degree if certainty is unassessable suggested 84 % decrease in arrhythmia but the degree if certainty is unassessable | ||||
Immunostimulants drugs | suggested 26 % decrease in deaths demonstrated 20 % increase in clinical improvement (time to event analysis only) | inconclusive results for: 14-days deaths; death D28; death or transfer to ICU; deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (28-day); clinical improvement (7-day); hospital discharge; mechanical ventilation; mechanical ventilation (time to event analysis only); radiologic improvement (14-day); viral clearance ; viral clearance by day 14; off oxygenation; serious adverse events; superinfection; adverse events | - | - | ||
corticosteroids | none | inconclusive results for: death D28; deaths; deaths (time to event analysis only); clinical deterioration; clinical improvement; clinical improvement (14-day); clinical improvement (time to event analysis only); death or ventilation; hospital discharge; mechanical ventilation; serious adverse events; superinfection | - | |||
anti-inflammatory therapies | none | inconclusive results for: death D28; deaths; clinical deterioration; clinical improvement (28-day); clinical improvement (time to event analysis only); hospital discharge; mechanical ventilation; serious adverse events; adverse events | suggested 10.3-fold increase in clinical improvement but the degree if certainty is unassessable | - | ||
Apilimod | 0 | - | - | - | - | |
inhaled corticosteroids | 0 | - | - | - | - | |
Kinase inhibitors | 0 | - | - | - | - | |
leflunomide | 0 | - | - | - | - | |
meplazumab | 0 | - | - | - | - | |
pirfenidone | 0 | - | - | - | - | |
Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
sargramostim | 0 | - | - | - | - | |
statins | 0 | - | - | - | - | |
thymosin | 0 | - | - | - | - |